Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Chronic Weight Management
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The following link used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
Making a positive difference in people’s lives is at the heart of everything Novo Nordisk does – through groundbreaking science, sustained focus on the environment, and patient-centered care.
Our Media Relations team is ready to help you get all the information you need about Novo Nordisk.
Findings from CONFIRM – a large, retrospective real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) 100 U/mL, 200 U/mL versus insulin glargine...
Ozempic® (semaglutide) injection 0.5 mg or 1 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass...
Oral semaglutide, an investigational GLP-1 receptor agonist taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to...
Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin glargine U-100 (1.94% vs 1.68% respectively;...
Visit the download center to download Novo Nordisk video and more
Sign up to receive our new alerts